The global antiepileptic drugs (AED) market size was valued at USD 17.891 billion in 2022. It is projected to reach USD 24.712 billion by 2031, growing at a CAGR of 4.12% during the forecast period (2023-2031).
Anti-epileptic medications are frequently used by people who have seizures. In epilepsy, brief disruptions in brain activity called seizures caused by electrical activity spikes occur repeatedly. Seizures can cause various symptoms, from tremors and shaking to memory loss and strange feelings. Various illnesses outside epilepsy are now being treated with anti-epileptic drugs (AEDs), including migraine prophylaxis, neuropathic pain, and bipolar disorder. Anti-epileptic drugs have progressed through three generations since their introduction. Bromide, phenobarbital, primidone, carbamazepine, and others were developed in the "1857-1970" period; Felbamate, lamotrigine, levetiracetam, and others were developed in the "1989-2007" period; and lacosamide, eslicarbazepine acetate, and clobazam were developed in the "2010-2018" period.
Over time, both generalized and partial epileptic seizures have become more commonplace worldwide. As a result, an increasing number of pharmaceutical companies are investing in creating improved anti-epileptic drugs to improve quality of life, lower incidence, and mitigate harmful side effects, all of which add to the disease burden on the planet. Government spending on healthcare, rising public knowledge of the benefits of innovative therapies, and rising interest in customized medicine are expected to drive market growth.
-market.jpg)
The increasing number of anti-epileptic pharmaceuticals approved by regulatory agencies is expected to drive the global market expansion for these drugs. Market growth in regions like Europe is expected to be driven by the increased prevalence of epilepsy over the forecast period. In 2015, the European Journal of Neurology reported that 4.5 to 5.0 per 1,000 children and adolescents in Europe were living with active epilepsy and that each year there were an estimated 130,000 new cases of epilepsy among children and adolescents, for an incidence rate of 70 per 100,000. Increases in inorganic growth techniques, such as collaborations between large companies, are also expected to contribute to the market's expansion over the forecast period.
Although AEDs are widely available, one-third of the population suffers from medication intolerance. The producers are addressing this issue in several ways. Recently, the focus of R&D has been on developing medications that specifically target the neurobiology underlying the disease condition. AEDs are being introduced due to market pressures caused by the increasing prevalence of epilepsy and the demand for therapeutically effective medications. The FDA's critical decision benefits patients and participants can better advance R&D. For example, in January 2020, the USFDA approved Valtoco, a nasal spray used to treat epilepsy in patients six years of age and older.
Similarly, the USFDA approved Epidiolex in June 2018 to treat patients with rare forms of epilepsy. This is the first pharmaceutical product that contains an active ingredient derived from marijuana. The approval committee's decisions help producers provide potential treatments to epilepsy patients, driving the global market.
The antiepileptic medicines market is struggling to expand despite the rising prevalence of epilepsy, seizures, and other chronic illnesses in developing nations. The sharp uptick in drug supply shortfall is one of the key challenges limiting industry expansion. Due to a lack of availability, patients are hoarding these medications. This has prompted concerns about the worldwide drug supply chain. In the United Kingdom and other European countries like Britain, this tragic situation is worsening due to Brexit uncertainty. As a result, the United Kingdom is losing its appeal as a market for drugs used to treat epilepsy, which has repercussions for the international market.
The International League Against Epilepsy (ILAE) describes over 30% of people with epilepsy who do not respond to well-known anti-seizure medications (ASMs) as being "drug-resistant," which refers to patients who do not respond to the combination of two carefully chosen and administered anti-seizure medications (ASMs). In order to improve patient symptoms, their quality of life (QoL), and that of the caregivers, there is a great deal of responsibility placed on the research and development of novel pharmacological and non-pharmacological therapies. The path for the opportunistic expansion of the global market for antiepileptic medications will be established by a sizable clinical pipeline and investigational research to develop innovative antiepileptic drugs for pediatric and geriatric patients.
| Study Period | 2020-2032 | CAGR | 4.12% |
| Historical Period | 2020-2022 | Forecast Period | 2024-2032 |
| Base Year | 2023 | Base Year Market Size | USD XX Billion |
| Forecast Year | 2032 | Forecast Year Market Size | USD XX Billion |
| Largest Market | North America | Fastest Growing Market | Asia Pacific |
Based on region, the global antiepileptic drugs (AED) market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
North America is the most significant global antiepileptic drugs (AED) market shareholder and is expected to grow at a significant CAGR over the forecast period. Greater neurological disease diagnosis, treatment rates, and suitable reimbursement policies for epilepsy medications distinguish the regional market. These elements, together with greater patient population awareness of novel treatment choices and the availability of cutting-edge epilepsy medications in the region, account for the region's dominant market share worldwide. Market growth in North America is anticipated to be led by factors such as the region's increasing epilepsy prevalence and strategic initiatives, awareness campaigns, and product launches by market players.
In addition, the market is expanding because more drugs are being approved for use in various age groups. For instance, in August of 2021, the FDA approved UCB's BRIVIACT (brivaracetam) CV tablets, oral solution, and injection for the treatment of partial-onset seizures in patients as young as one month old. The first IV formulation of BRIVIACT is now available for use when oral administration is not feasible. This IV formulation is among the first to receive FDA approval for the treatment of partial-onset seizures in children as young as a month old (nearly seven years old). Furthermore, the prevalence of epilepsy in the United States is also being brought to light by several advocacy groups. For instance, every year on March 26th, people worldwide observe Epilepsy Awareness Day (also known as Purple Day) to raise awareness about this brain disorder and dispel associated myths and prejudices.
Asia-Pacific is projected to grow significantly over the forecast period. Increased approvals of antiepilepsy medications by the European Medicines Agency (EMA) in 2018 and 2019 are expected to boost demand for anticonvulsants in Europe over the forecast period. The revenue from the epilepsy medications market in Asia-Pacific is anticipated to increase over the forecast period due to anticipated regulatory approvals in the region and the expansion of major players.
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
The global antiepileptic drugs (AED) market is segmented into drug generation and distribution channels.
Based on the drug generation, the global market is bifurcated into first-generation, second-generation, and third-generation.
The second-generation segment owns the highest market share and is expected to grow significantly over the projected period. Drugs from the second generation include Banzel, Keppra, and Lyrica. Lyrica is the market leader for the treatment of epilepsy in terms of market share. It has demonstrated its promise for reducing brain impulses and regulating seizures. In addition, Pfizer's Lyrica dominated the epilepsy market until its patent expired in 2019. However, the drug is still in demand because of its benefits. Other second-generation medications have also demonstrated their ability to lessen epilepsy symptoms.
Drugs of the third generation, including Vimpat, Briviact, and others, are widely available and effective in treating epilepsy. The demand for UCB's Vimpat is swiftly rising in the epilepsy markets of the United States, Europe, and Japan. Due to the introduction of new drugs and rising spending on drug R&D, this category is predicted to develop quickly. Briviact, for instance, was granted USFDA approval by UCB to treat pediatric epilepsy patients' partial-onset seizures. The patent expiration of second-generation pharmaceuticals also allows producers to introduce new therapies. As a result of falling demand, first-generation pharmaceuticals can anticipate slower market expansion.
Based on the distribution channel, the global market is split into hospital pharmacies, retail pharmacies, and online pharmacies.
The hospital pharmacies segment is the highest contributor to the market and is expected to grow significantly over the forecast period. In industrialized and developing nations, hospital pharmacies for neurology, cardiology, and other disorders are rising, drawing a sizable patient population with acute and chronic illnesses. Most of these individuals are patients receiving care at hospitals with cutting-edge technology and adequate facilities. According to estimates, the hospital pharmacy segment holds most of the market. In addition, an increasing percentage of epilepsy patients are treated in hospitals due to a growing number of hospitals and acceptable reimbursement policies offered by these settings, among other things. This ultimately led to hospital pharmacies all around the world using antiepileptic medications.
Retail pharmacies are predicted to develop quickly due to these facilities' increased use of epilepsy medications. Epilepsy medications being easily accessible to patients in pharmacies will drive the retail pharmacies' segmental expansion over the predicted period.
